vs
EXACT SCIENCES CORP（EXAS）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是VERACYTE, INC.的6.2倍（$878.4M vs $140.6M）。VERACYTE, INC.净利率更高（29.3% vs -9.8%，领先39.0%）。EXACT SCIENCES CORP同比增速更快（23.1% vs 18.5%）。EXACT SCIENCES CORP自由现金流更多（$120.4M vs $48.8M）。过去两年VERACYTE, INC.的营收复合增速更高（20.5% vs 17.4%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
EXAS vs VCYT — 直观对比
营收规模更大
EXAS
是对方的6.2倍
$140.6M
营收增速更快
EXAS
高出4.6%
18.5%
净利率更高
VCYT
高出39.0%
-9.8%
自由现金流更多
EXAS
多$71.6M
$48.8M
两年增速更快
VCYT
近两年复合增速
17.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $140.6M |
| 净利润 | $-86.0M | $41.1M |
| 毛利率 | 70.1% | 72.5% |
| 营业利润率 | -9.4% | 26.4% |
| 净利率 | -9.8% | 29.3% |
| 营收同比 | 23.1% | 18.5% |
| 净利润同比 | 90.1% | 704.8% |
| 每股收益（稀释后） | $-0.45 | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASVCYT
| Q4 25 | $878.4M | $140.6M | ||
| Q3 25 | $850.7M | $131.9M | ||
| Q2 25 | $811.1M | $130.2M | ||
| Q1 25 | $706.8M | $114.5M | ||
| Q4 24 | $713.4M | $118.6M | ||
| Q3 24 | $708.7M | $115.9M | ||
| Q2 24 | $699.3M | $114.4M | ||
| Q1 24 | $637.5M | $96.8M |
净利润EXASVCYT
| Q4 25 | $-86.0M | $41.1M | ||
| Q3 25 | $-19.6M | $19.1M | ||
| Q2 25 | $-1.2M | $-980.0K | ||
| Q1 25 | $-101.2M | $7.0M | ||
| Q4 24 | $-864.6M | $5.1M | ||
| Q3 24 | $-38.2M | $15.2M | ||
| Q2 24 | $-15.8M | $5.7M | ||
| Q1 24 | $-110.2M | $-1.9M |
毛利率EXASVCYT
| Q4 25 | 70.1% | 72.5% | ||
| Q3 25 | 68.6% | 69.2% | ||
| Q2 25 | 69.3% | 69.0% | ||
| Q1 25 | 70.8% | 69.5% | ||
| Q4 24 | 69.0% | 66.4% | ||
| Q3 24 | 69.4% | 68.2% | ||
| Q2 24 | 69.8% | 68.1% | ||
| Q1 24 | 70.0% | 64.5% |
营业利润率EXASVCYT
| Q4 25 | -9.4% | 26.4% | ||
| Q3 25 | -3.0% | 17.4% | ||
| Q2 25 | -0.3% | -4.0% | ||
| Q1 25 | -13.6% | 2.5% | ||
| Q4 24 | -122.8% | 3.5% | ||
| Q3 24 | -5.6% | 10.4% | ||
| Q2 24 | -3.8% | 4.0% | ||
| Q1 24 | -16.7% | -4.8% |
净利率EXASVCYT
| Q4 25 | -9.8% | 29.3% | ||
| Q3 25 | -2.3% | 14.5% | ||
| Q2 25 | -0.1% | -0.8% | ||
| Q1 25 | -14.3% | 6.2% | ||
| Q4 24 | -121.2% | 4.3% | ||
| Q3 24 | -5.4% | 13.1% | ||
| Q2 24 | -2.3% | 5.0% | ||
| Q1 24 | -17.3% | -1.9% |
每股收益（稀释后）EXASVCYT
| Q4 25 | $-0.45 | $0.50 | ||
| Q3 25 | $-0.10 | $0.24 | ||
| Q2 25 | $-0.01 | $-0.01 | ||
| Q1 25 | $-0.54 | $0.09 | ||
| Q4 24 | $-4.69 | $0.07 | ||
| Q3 24 | $-0.21 | $0.19 | ||
| Q2 24 | $-0.09 | $0.07 | ||
| Q1 24 | $-0.60 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $362.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $1.3B |
| 总资产 | $5.9B | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASVCYT
| Q4 25 | $964.7M | $362.6M | ||
| Q3 25 | $1.0B | $315.6M | ||
| Q2 25 | $858.4M | $219.5M | ||
| Q1 25 | $786.2M | $186.1M | ||
| Q4 24 | $1.0B | $239.1M | ||
| Q3 24 | $1.0B | $274.1M | ||
| Q2 24 | $946.8M | $235.9M | ||
| Q1 24 | $652.1M | $209.2M |
股东权益EXASVCYT
| Q4 25 | $2.4B | $1.3B | ||
| Q3 25 | $2.5B | $1.3B | ||
| Q2 25 | $2.5B | $1.2B | ||
| Q1 25 | $2.4B | $1.2B | ||
| Q4 24 | $2.4B | $1.2B | ||
| Q3 24 | $3.2B | $1.2B | ||
| Q2 24 | $3.2B | $1.1B | ||
| Q1 24 | $3.1B | $1.1B |
总资产EXASVCYT
| Q4 25 | $5.9B | $1.4B | ||
| Q3 25 | $5.9B | $1.4B | ||
| Q2 25 | $5.8B | $1.3B | ||
| Q1 25 | $5.7B | $1.3B | ||
| Q4 24 | $5.9B | $1.3B | ||
| Q3 24 | $6.7B | $1.3B | ||
| Q2 24 | $6.7B | $1.2B | ||
| Q1 24 | $6.4B | $1.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $52.6M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $48.8M |
| 自由现金流率自由现金流/营收 | 13.7% | 34.7% |
| 资本支出强度资本支出/营收 | 3.6% | 2.7% |
| 现金转化率经营现金流/净利润 | — | 1.28× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $126.6M |
8季度趋势，按日历期对齐
经营现金流EXASVCYT
| Q4 25 | $151.7M | $52.6M | ||
| Q3 25 | $219.9M | $44.8M | ||
| Q2 25 | $89.0M | $33.6M | ||
| Q1 25 | $30.8M | $5.4M | ||
| Q4 24 | $47.1M | $24.5M | ||
| Q3 24 | $138.7M | $30.0M | ||
| Q2 24 | $107.1M | $29.6M | ||
| Q1 24 | $-82.3M | $-9.0M |
自由现金流EXASVCYT
| Q4 25 | $120.4M | $48.8M | ||
| Q3 25 | $190.0M | $42.0M | ||
| Q2 25 | $46.7M | $32.3M | ||
| Q1 25 | $-365.0K | $3.5M | ||
| Q4 24 | $10.7M | $20.4M | ||
| Q3 24 | $112.6M | $27.7M | ||
| Q2 24 | $71.2M | $26.8M | ||
| Q1 24 | $-120.0M | $-11.1M |
自由现金流率EXASVCYT
| Q4 25 | 13.7% | 34.7% | ||
| Q3 25 | 22.3% | 31.8% | ||
| Q2 25 | 5.8% | 24.8% | ||
| Q1 25 | -0.1% | 3.1% | ||
| Q4 24 | 1.5% | 17.2% | ||
| Q3 24 | 15.9% | 23.9% | ||
| Q2 24 | 10.2% | 23.4% | ||
| Q1 24 | -18.8% | -11.5% |
资本支出强度EXASVCYT
| Q4 25 | 3.6% | 2.7% | ||
| Q3 25 | 3.5% | 2.1% | ||
| Q2 25 | 5.2% | 1.0% | ||
| Q1 25 | 4.4% | 1.6% | ||
| Q4 24 | 5.1% | 3.5% | ||
| Q3 24 | 3.7% | 1.9% | ||
| Q2 24 | 5.1% | 2.4% | ||
| Q1 24 | 5.9% | 2.2% |
现金转化率EXASVCYT
| Q4 25 | — | 1.28× | ||
| Q3 25 | — | 2.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.76× | ||
| Q4 24 | — | 4.80× | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 5.16× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
VCYT
| Testing | $135.8M | 97% |
| Products | $3.8M | 3% |
| Biopharmaceutical And Other | $686.0K | 0% |
